A Trial to Evaluate a Device for the Treatment of OSA and Snoring (OPEN)
Primary Purpose
Obstructive Sleep Apnea, Snoring
Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Tongue Advancement Retainer Device
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring Obstructive Sleep Apnea, OSA, Snoring, Tongue Advancement Retainer Device
Eligibility Criteria
Inclusion Criteria:
• Aged 18-65
- AHI greater than or equal to 10 but less than or equal to 60 (<10 AHI <60/hr)
- Complete set of lower anterior incisors with no evidence of periodontal disease or mobility and the ability to floss between teeth
Additionally subjects will in the screening phase must:
- Tolerate the device when being fitted
- Used the device for >4 hours on at least two consecutive nights during the screening period.
- Be able to reliably demonstrate proper installation of the device after fitting.
- Be willing to trial the device for a 4 week period
Exclusion Criteria:
• Central sleep apnea events >10% of the total events
- Evidence of Cheyne stokes breathing
- Currently on treatment for OSA or OSA treatment discontinued less than 3 months prior.
- Currently on regular treatment with prescription hypnosedatives or prescription stimulants
- Very severe OSA, defined as AHI>60/hour and/or minimum oxygen saturation <75%
- Need for immediate initiation of treatment as assessed by physician (e.g. Excessive sleepiness posing driving risk)
- Previous surgery to treat OSA (other than nasal surgery)
- Evidence of periodontal disease or tooth mobility
- Severe nasal obstruction or enlarged tonsils based on clinical assessment
- Unstable cardiovascular disease (untreated hypertension acceptable).
- Inability to tolerate oral device due to oral condition or claustrophobia as determined by the study investigator
- Pregnant/Breast Feeding
- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as co-existent other sleep disorder, psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements.
Sites / Locations
- Senta Clinic
- Visalia Medical Clinic
- Royal North Shore Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Device Treatment
Arm Description
Tongue Advancement Retainer Device
Outcomes
Primary Outcome Measures
Primary Safety Endpoint - The safety of the device will be measured through recorded observations of adverse events.
Safety endpoint will be measured throughout the duration of the study.
Secondary Outcome Measures
Primary Efficacy Endpoint - Change in the overall Apnea Hypopnea Index (AHI) from the PSG at baseline and end of treatment phase.
Efficacy Endpoint will be measured at baseline and at end of treatment.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01772017
Brief Title
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
Acronym
OPEN
Official Title
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Terminated
Why Stopped
Sponsor decided to discontinue study for business reasons.
Study Start Date
October 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sleepy, Inc
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the safety and efficacy of the Tongue Advancement Retainer Device in treating subjects with Obstructive Sleep Apnea (OSA) and snoring.
Detailed Description
The Tongue Advancement Retainer Device is a device that was developed to treat subjects with OSA and snoring. The purpose of this study is to evaluate initial safety and effectiveness of this device in treating one or both conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea, Snoring
Keywords
Obstructive Sleep Apnea, OSA, Snoring, Tongue Advancement Retainer Device
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Device Treatment
Arm Type
Experimental
Arm Description
Tongue Advancement Retainer Device
Intervention Type
Device
Intervention Name(s)
Tongue Advancement Retainer Device
Other Intervention Name(s)
Sleepy Tongue Advancement Retainer Device
Intervention Description
Tongue Advancement Retainer Device
Primary Outcome Measure Information:
Title
Primary Safety Endpoint - The safety of the device will be measured through recorded observations of adverse events.
Description
Safety endpoint will be measured throughout the duration of the study.
Time Frame
Approximately 6 weeks
Secondary Outcome Measure Information:
Title
Primary Efficacy Endpoint - Change in the overall Apnea Hypopnea Index (AHI) from the PSG at baseline and end of treatment phase.
Description
Efficacy Endpoint will be measured at baseline and at end of treatment.
Time Frame
Approximately 6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
• Aged 18-65
AHI greater than or equal to 10 but less than or equal to 60 (<10 AHI <60/hr)
Complete set of lower anterior incisors with no evidence of periodontal disease or mobility and the ability to floss between teeth
Additionally subjects will in the screening phase must:
Tolerate the device when being fitted
Used the device for >4 hours on at least two consecutive nights during the screening period.
Be able to reliably demonstrate proper installation of the device after fitting.
Be willing to trial the device for a 4 week period
Exclusion Criteria:
• Central sleep apnea events >10% of the total events
Evidence of Cheyne stokes breathing
Currently on treatment for OSA or OSA treatment discontinued less than 3 months prior.
Currently on regular treatment with prescription hypnosedatives or prescription stimulants
Very severe OSA, defined as AHI>60/hour and/or minimum oxygen saturation <75%
Need for immediate initiation of treatment as assessed by physician (e.g. Excessive sleepiness posing driving risk)
Previous surgery to treat OSA (other than nasal surgery)
Evidence of periodontal disease or tooth mobility
Severe nasal obstruction or enlarged tonsils based on clinical assessment
Unstable cardiovascular disease (untreated hypertension acceptable).
Inability to tolerate oral device due to oral condition or claustrophobia as determined by the study investigator
Pregnant/Breast Feeding
Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as co-existent other sleep disorder, psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian Weeks, MD
Organizational Affiliation
Senta Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Senta Clinic
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
Visalia Medical Clinic
City
Visalia
State/Province
California
ZIP/Postal Code
93291
Country
United States
Facility Name
Royal North Shore Hospital
City
St. Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
12. IPD Sharing Statement
Learn more about this trial
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
We'll reach out to this number within 24 hrs